Vertex Pharmaceuticals
VRTX
1,286 hedge funds and large institutions have $83.3B invested in Vertex Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 142 funds opening new positions, 486 increasing their positions, 488 reducing their positions, and 59 closing their positions.
141% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 59
38% more funds holding in top 10
Funds holding in top 10: 24 → 33 (+9)
19% more call options, than puts
Call options by funds: $474M | Put options by funds: $397M
11% more capital invested
Capital invested by funds: $75B → $83.3B (+$8.31B)
6% more funds holding
Funds holding: 1,208 → 1,286 (+78)
0% less repeat investments, than reductions
Existing positions increased: 486 | Existing positions reduced: 488
0.84% less ownership
Funds ownership: 93.2% → 92.36% (-0.84%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$759M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$403M |
| 3 |
Millennium Management
New York
|
+$357M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$219M |
| 5 |
Morgan Stanley
New York
|
+$144M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$555M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$386M |
| 3 |
BlackRock
New York
|
-$366M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$282M |
| 5 |
Jennison Associates
New York
|
-$261M |
VRTX Hedge Fund Activity: Q2 2023 in Review
1,286 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2023, worth a combined $83.3B — up 11% from $75B a quarter earlier.
Buyers outnumbered sellers: 142 funds opened new VRTX positions and 59 closed out — a net gain of 83 holders — while 486 added to existing stakes and 488 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $759M. The largest seller was Fidelity Investments, cutting an estimated $555M.
- 1,286 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2023, up from 1,208 in Q1 2023.
- Funds reported $83.3B of Vertex Pharmaceuticals stock for Q2 2023, up 11% quarter-over-quarter.
- 142 funds opened new Vertex Pharmaceuticals positions in Q2 2023 and 59 closed out, a net change of +83 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2023 was Capital Research Global Investors, an estimated $759M added.
- The largest Vertex Pharmaceuticals seller in Q2 2023 was Fidelity Investments, an estimated $555M sold.
Based on aggregated 13F filings for Q2 2023.